Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

NCT07327359 is registered in ClinicalTrials.gov with Olix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07327359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07327359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
Lead sponsor
Olix Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 4, 2025
Completion date
September 30, 2027
Enrollment
158 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia (aga)